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Treatment with lamivudine of patients infected with hepatitis B virus (HBV) results in a high 
rate of drug resistance, which is primarily associated with the rtm204I/V substitution in the 
HBV reverse transcriptase domain. Here we show that the rtm204I/V substitution, although 
essential, is insufficient for establishing resistance against lamivudine. The analysis of 639 HBV 
whole-genome sequences obtained from 11 patients shows that rtm204I/V is independently 
acquired  by  more  than  one  intra-host  HBV  variant,  indicating  the  convergent  nature  of 
lamivudine resistance. The differential capacity of HBV variants to develop drug resistance 
suggests that fitness effects of drug-resistance mutations depend on the genetic structure of 
the HBV genome. An analysis of Bayesian networks that connect rtm204I/V to many sites of 
HBV proteins confirms that lamivudine resistance is a complex trait encoded by the entire HBV 
genome rather than by a single mutation. These findings have implications for public health and 
offer a more general framework for understanding drug resistance. 
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H
epatitis B virus (HBV) causes chronic infection in >350 mil-
lion people worldwide. Cirrhosis, liver failure and hepato-
cellular carcinoma associated with chronic HBV infections 
account for ~1 million deaths annually1. The HBV genome consists 
of partially double-stranded DNA of ~3,200 base pairs that repli-
cates via reverse transcription of the pregenomic RNA2. Treatment 
of  chronically  infected  patients  with  nucleos(t)ide  analogues  to 
inhibit the HBV reverse transcriptase (RT) suppresses HBV replica-
tion and reduces the risk of liver disease progression. Long-term 
treatment with RT inhibitors, however, leads to the development of 
drug resistance3,4. Lamivudine is one of five RT inhibitors approved 
for treatment of patients with chronic hepatitis B, and widely used 
across the world. Lamivudine therapy leads to the appearance of 
drug-resistant HBV variants in 14–32% of patients during the first 
year of treatment and ~70% of patients after 5 years3. Lamivudine 
resistance is primarily associated with rtM204I or rtM204V substi-
tution (rtM204I/V) in the YMDD motif of the RT domain. Other 
mutations that have been reported to be associated with lamivudine 
resistance include rtA181V/T and several secondary RT mutations, 
for example, rtV173L and rtL180M3.
It is estimated that a high rate of mutations in the HBV genome 
readily results in emergence of all single mutations during chronic HBV 
infection5. Thus, drug-resistance mutations might be present in infected 
patients even without selective pressure from antiviral drugs. However, 
the ubiquity of drug-resistance mutations does not completely explain 
variation in the rate and type of drug resistance in patients receiving 
antiviral therapy. Besides the size of the viral population, which sig-
nificantly affects the presentation of specific mutations, epistatic con-
nectivity among HBV genomic sites can have a very important role in 
establishing the drug-resistance phenotype6. Genetic analysis of resist-
ance to nucleos(t)ide inhibitors is usually focused on the RT domain 
and only infrequently takes into consideration the whole genome of 
intra-host HBV variants6–8. This limits evaluation of epistatic connec-
tivity across the viral genome and its association to drug resistance.
In this study, we analysed a large set of whole-genome sequences 
of the intra-host HBV variants recovered from 11 HBV-infected 
patients, who were undergoing lamivudine treatment, and showed 
the important contribution of convergence and site coevolution in 
lamivudine resistance.
Results
Intra-host population of lamivudine-resistant HBV variants. HBV 
whole-genome quasispecies were sampled from 11 patients who 
experienced virological breakthrough during lamivudine treatment 
(Table 1). A total of 395 whole-HBV genomes were sequenced using 
end-point limiting-dilution RT–polymerase chain reaction (PCR)9. 
On an average, 36 HBV genomes were sampled from each patient. 
Patients  were  infected  with  HBV  genotypes  A  (n = 4),  B  (n = 1),   
C (n = 2) and D (n = 2). Patient 1 was infected with mixed genotypes 
A and G, and Patient 9 with a recombinant genotype A/G strain 
(Table 1). The rtM204I/V substitution was detected in all patients 
except Patient 9. This patient did not have any known lamivudine-
resistance-associated mutations.
Analysis of mutations in the YMDD motif showed that intra-
host HBV populations may have more than one type of lamivudine-
resistance mutations. For example, the HBV genotype A variants in 
Patient 1 contained the rtM204V substitution, whereas variants of 
genotype G in the same patient contained rtM204I (Fig. 1). Codon 
usage additionally contributed to the genetic heterogeneity under-
lying lamivudine-resistance. For example, ATC coding for isoleu-
cine in YIDD was found in one genome among the ten genotype G 
variants in Patient 1, while all other variants contained ATT. Patient 
4 was infected with two HBV genotype B subpopulations (Fig. 1), 
both containing the rtM204I substitution. However, in one subpop-
ulation the isoleucine was encoded by ATC, whereas in the other 
subpopulation it was encoded by ATT. Nine of ten HBV variants 
containing ATC (Fig. 1) harboured additional substitution rtA181T 
that also confers decreased susceptibility to lamivudine and adefo-
vir10. In Patient 10, 23% of all variants contained the rtM204I sub-
stitution, whereas the remainder contained rtM204V. Among 44 
HBV variants identified in Patient 3, 43 contained rtM204I, while 
1 variant contained rtM204V. This variant was different from the 
major cluster at a minimum of six positions. It was one of two most 
genetically distinct variants (Fig. 1) and thus, represents a minority 
HBV subpopulation.
All the HBV variants in Patients 5 and 6 contained rtM204I or 
rtM204V, respectively. However, in Patient 5, one variant differed 
from all other variants at eight positions and contained two dele-
tions of 30 and 57 bp in the preS1 region (Fig. 1). In Patient 6, a single 
Table 1 | Virological characteristics and YMDD patterns of patients on lamivudine treatment.
Patient ID Age/sex Genotype Before lamivudine treatment After lamivudine treatment
HBV load* No. of 
clones
No. of 
unique 
clones
YMDD 
mutation 
(%)
HBV 
load*
No. clones No. unique 
clones
YMDD mutation 
(%)
1 44/m A/G† — — — — 10.2 40 25‡ m204I (65%), 
m204 V (35%)
2 53/m D — — — — 8.8 45 25 m204I (100%)
3 54/F C — — — — 7.9 44 27 m204I (98%), 
m204 V (2%)
4 54/m B — — — — 9.2 41 34 m204I (100%)
5 64/F C — — — — 6.4 12 7 m204I (100%)
6 8/m A 9.3 41 29 m204I (2%) 7.9 45 21 m204 V (100%)
7 59/m A 12.8 36 29 no 9.9 34 19 m204 V (100%)
8 37/m D 8.9 41 36 no 8.9 40 19 m204 V (98%)
9 38/m A/G¶ 11.6 36 35 m204I (3%) 9.5 31 20 none
10 44/m A 9.2 44 43 no 10.5 35 35 m204 V (74%), 
m204I (23%)
11 57/m A 12.3 46 46 no 10.9 28 26 m204 V (100%)
Abbreviations: F, female; m, male.
*log10 Iu ml − 1.
†mixed HBV genotypes A and G.
‡A total of 25 clones were sequenced, among which 15 belonged to HBV genotype A and 10 to HBV genotype G.
¶Clones belonged to genotype G and recombinant genotype A/G before treatment and to recombinant genotype A/G after treatment.ARTICLE     
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variant was found to be different from the main HBV cluster at 24 
positions, with one substitution that additionally changed YVDD to 
YVND (Fig. 1). Patient 9, who developed drug resistance through a 
YMDD-unrelated mechanism, also contained one HBV-outlier var-
iant, which differed from the main intra-host HBV population at 19 
positions. Thus, Patients 5, 6 and 9 were infected with complex lami-
vudine-resistant HBV populations that contained distinct minority 
variants. Collectively, the aforementioned observations indicate that 
lamivudine resistance was independently acquired by more than 
one HBV variant in each patient studied, and point to the frequent 
availability of the lamivudine-resistance mutations and homoplastic 
nature of the resistance in intra-host HBV populations.
Lamivudine-induced changes in intra-host HBV populations. To 
analyse adaptation of intra-host HBV populations to lamivudine 
treatment,  whole-genome  sequences  of  intra-host  HBV  variants 
from pre-treatment samples (n = 244) were additionally analysed 
in Patients 6–11. Comparison of the variants showed considerable 
changes in the genetic structure of intra-host HBV populations dur-
ing treatment (Fig. 2). HBV populations identified before and after 
treatment were distinctly different in all patients. In Patients 6 and 
9, the rtM204I substitution was identified in a single clone of pre-
treatment HBV populations but these clones were not present in 
their post-treatment populations (Table 1).
The pre-treatment HBV variants in Patients 8 and 9 were organ-
ized  into  two  major  subpopulations.  Interestingly,  their  HBV 
genetic diversity was greatly reduced after treatment, when only a 
single subpopulation successfully established lamivudine resistance 
(Fig. 2). The subpopulation, which was not found after treatment in 
Patient 8, contained a large deletion of 183 bp in the preS region at 
positions 2,984–3,166. Although Patient 9 was infected with geno-
type G and recombinant genotype A/G variants, no constituents of 
the genotype G subpopulation were identified after treatment. The 
finding is surprising because the genotype G subpopulation con-
tained a variant manifesting rtM204I. These observations in the 
two patients indicate significant differences in the capacity to evolve 
toward lamivudine resistance among the intra-host HBV variants.
In Patient 7, the HBV genetic diversity, as measured by Shannon   
entropy (Sn), was also significantly reduced after treatment (6.3× 
10 − 4 versus 3.6×10 − 4; paired samples t-test, P = 0.0085). The HBV 
genetic diversity was not significantly different in Patient 6 (paired 
samples t-test, P = 0.7104) and Patient 11 (paired samples t-test, 
P = 0.0849). The HBV genetic diversity was significantly increased 
after  treatment  only  in  Patient  10  (1.1×10 − 3  versus  2.3×10 − 3; 
paired  samples  t-test;  P < 0.0001).  The  frequency  distribution  of 
HBV variants was similar in Patients 6, 7, 10 and 11 before and after 
therapy (Fig. 3). HBV populations in Patients 6 and 7 contained 
high-frequency variants, with only ~47–80% of all sampled HBV 
sequences being unique. The star-like phylogeny of HBV popula-
tions in these two patients after treatment (Fig. 3) is consistent with 
derivation of these populations from a single lamivudine-resistant 
HBV variant. However, the complexity of the populations did not 
significantly change following treatment, so whether lamivudine-
resistant populations originated from a single variant is uncertain. 
By contrast, 93–100% of HBV variants in Patients 10 and 11 were 
unique; suggesting that adaptation to lamivudine was not associ-
ated with strong bottleneck events.
We identified a total of 81 sites in the HBV genome that showed 
significant  changes  (analysis  of  molecular  variance  (AMOVA), 
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Figure 1 | Maximum likelihood trees of intra-host HBV variants sampled 
from patients after lamivudine treatment. The node size is proportional 
to frequency of the corresponding variant in the viral population. Colours 
correspond to the codon states at position rt204: rtm204I coded by ATT 
or ATC is shown in red or grey, respectively; rtm204V is shown in blue 
(codon GTG); the wild type is shown in cyan (codon ATG). The distance 
between the two genotype clusters of Patient 1 was plotted 20 times 
shorter to allow the visualization of minor variants.
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Figure 2 | Maximum likelihood trees of intra-host HBV variants from six 
patients. HBV populations sampled from patients infected with genotypes 
A (n = 4), D (n = 1), G (n = 1) before (open circles) and after (colour-filled 
circles) lamivudine treatment. Each colour presents a single patient.ARTICLE
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P < 0.05) in nucleotide frequencies between pre- and post-treatment 
populations of all six patients. In Patients 8 and 9, only subpopu-
lations that persisted post treatment were considered for analysis. 
HBV populations in Patients 6 and 7 had significant changes at 5 
sites, those in Patient 9 at 7 sites, and those in Patients 8, 10 and 
11 at 26, 27 and 25 sites, respectively. Exclusion of the correspond-
ing sites from phylogenetic analysis of HBV variants in each patient 
resulted in complete intermixing of both pre- and post-treatment 
HBV populations, indicating essential reduction in genetic differ-
ences between these populations. The genetic distance between the 
pre- and post-treatment populations was different among patients, 
being approximately four to five times greater for Patients 8, 10 
and 11 than for Patients 6, 7 and 9. Besides the sites for the pri-
mary (rtM204V/I) and secondary (rtL180M) lamivudine-resistance 
mutations identified in five patients, only one additional site with 
significant changes in intra-host populations was shared by HBV in 
three patients and four sites by HBV in two patients. All other sites 
(n = 74) were unique for HBV in each patient, indicating a limited 
degree of common genetic changes during lamivudine treatment 
among HBV populations in the six patients.
Origin of lamivudine-resistant HBV populations. Phylogenetic 
analysis of HBV populations sampled from Patients 6 to 11 showed 
that some pre-treatment HBV variants were genetically close to the 
respective lamivudine-resistant population (Fig. 3), which seems 
to suggest that these variants served as sources for the resistant 
population. However, such a conclusion is not warranted for all 
six patients. Assuming parsimony of evolution toward lamivudine 
resistance, we calculated the average maximum likelihood (ML) 
distances among all HBV sequences to assess the origin of the lami-
vudine-resistant HBV variants. For Patients 8 and 9, the analysis 
was conducted using only pretreatment subpopulations, which were 
genetically closest to the resistant HBV variants.
Figure 4  shows a scatter plot of the distances for each patient, where 
each pre-treatment sequence is plotted according to two variables: 
first, its average distance to all other pre-treatment sequences(C), 
which is a measure of centrality of the sequence in the variant cloud 
at the time of sampling; and second, its average distance to all post-
treatment sequences (D), a measure of relatedness of the sequence 
to the lamivudine-resistant variants. It is important to note that, 
with the exception of HBV populations in Patients 10 and 11, the 
most central pretreatment sequences were also the most frequent. 
A significant positive correlation was found between these two vari-
ables for HBV populations in Patients 6, 7, 9, 10 and 11 (Patient 6: 
r = 0.9998, P = 1.82E − 43; Patient 7: r = 0.7034, P = 4.26E − 05; Patient 
9:  r = 0.8988,  P = 2.40E − 03;  Patient  10:  r = 0.7028,  P = 2.11E − 07; 
and  Patient  11:  r = 0.8433,  P = 1.91E − 13).  This  finding  indicates 
that post-treatment HBV populations are genetically close to the 
most central variants from pre-treatment HBV populations in the 
five patients. The supposition that lamivudine-resistant HBV popu-
lations  directly  originated  from  the  pre-existing  high-centrality   
variants is to some extent applicable to Patients 6 and 9 only, in 
whom the main post-treatment HBV populations differed from the   
pre-treatment variants at a few (n = 2–4) genomic positions (for 
Patient 9, only recombinant A/G subpopulation was considered.).
In Patient 6, one major post-treatment HBV variant differed from 
the major pre-treatment variant by only rtM204V and rtL180M. 
Nevertheless, close genetic relatedness to sequences with the high   
C value does not implicate a single source for the resistant HBV   
variants. Indeed, analysis of phylogenetic trees suggests that the lam-
ivudine-resistant populations in Patients 6 and 9 are polyphyletic 
(Fig. 3).
In Patient 7, HBV populations before and after treatment con-
tained two high-frequency variants. Strikingly, the major variants 
in each population differed from each other by the same substitu-
tion at the same position, rtP1S, and between populations by four 
wt
wt
Patient 6 Patient 7 Patient 8
Patient 9 Patient 10 Patient 11
Figure 3 | Maximum likelihood trees of intra-host HBV variants sampled before and after lamivudine therapy. HBV variants were sampled from 
Patients 6–11 before (blue) and after (red) treatment with lamivudine. The node size is proportional to frequency of the corresponding variant in the viral 
population. For Patients 8 and 9, only pre-treatment subpopulations that were genetically closest to the resistant variants are shown.ARTICLE     
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substitutions at the same positions, with two of these substitutions 
being rtM204V and rtL180M. Together with the finding of simi-
larity of the variant-frequency structure of pre- and post-treatment   
HBV  populations,  these  observations  suggest  that  two  major   
pre-therapy variants gave origin to two major lamivudine-resistant 
variants,  despite  the  pre-treatment  population  having  contained 
minority  variants  that  were  phylogenetically  closer  to  the  post-
treatment population (Fig. 3).
The post-treatment HBV population in Patient 10 did not contain 
high-frequency variants. The phylogenetic tree of this population 
has five major branches. One branch represents a cluster of closely 
related sequences that contain the rtM204I substitution whereas the 
other four branches contain rtM204V. One variant of this cluster is 
wild type, suggesting that it represents the pre-treatment minority 
HBV subpopulation, which served as a source for subsequent resist-
ant variants containing rtM204I. The complex phylogenetic struc-
ture of the post-treatment population constituted of highly diverse 
variants (Sn = 2.3×10 − 3), the presence of >1 type of lamivudine-
resistance substitutions, and the significantly large genetic distance 
of this population from the pre-treatment population indicate that 
many  lamivudine-resistant  variants  independently  evolved  from 
minority pre-treatment variants. The HBV population in Patient 11 
also did not contain high-frequency variants (Fig. 3). This similarity 
between Patients 10 and 11 suggests the extensive parallel evolution 
toward lamivudine resistance in Patient 11 as well. Thus, the phylo-
genetic relationships within the post-treatment HBV population in 
Patients 10 and 11 reflect phylogenetic relationships among imme-
diate ancestors of the lamivudine-resistant variants rather than a 
single-source origin of resistance.
HBV variants in Patient 8 showed negative correlation between 
C and D (Fig. 4; r =  − 0.6062; P = 1.69E − 03). Inspection of the phy-
logenetic tree readily shows that one minority pre-treatment sub-
population, which was composed of only 2 variants, was genetically 
close to the post-treatment population (Fig. 3). The post-treatment 
variant, which was closest to this subpopulation, was wild type, sug-
gesting that these three variants (two from pre- and one from post-
treatment populations) were related to a minority pre-treatment   
subpopulation that was a source for the lamivudine-resistant HBV 
variants. The departure from positive C/D correlation in this patient 
is  related  to  the  existence  of  more  than  one  genetically  distant 
minority subpopulations before therapy (Fig. 3).
Collectively, the data suggest that for Patients 8–11, minority 
HBV subpopulations existing before treatment were direct ancestors 
of the lamivudine-resistant HBV variants, whereas the subpopula-
tions that were dominant pre-therapy failed to become lamivudine-
resistant. For Patients 6 and 7, however, the lamivudine-resistant   
variants  mostly  originated  from  the  dominant  pre-treatment   
subpopulations.
Epistatic  connectivity  of  lamivudine-resistance  mutations.  The 
findings presented above indicate variation in the capacity of the intra-
host HBV subpopulations to develop drug resistance, suggesting that 
fitness effects of drug-resistance mutations significantly depend on 
the genetic structure of HBV genome. Accordingly, the lamivudine- 
resistance phenotype is a complex trait encoded by the entire HBV 
genome rather than by single mutations and as such should be defined 
by epistatic connections among HBV genomic sites, with the primary 
and secondary lamivudine-resistance mutations being involved in 
these connections. To investigate this epistatic connectivity, we con-
structed a set of Bayesian networks (BNs) of polymorphic amino-
acid sites in HBV proteins of pre-treatment and post-treatment viral 
populations from each patient (Fig. 5). For Patients 8 and 9, BNs were 
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Figure 4 | Scatterplot of distances among intra-host HBV variants of 
six patients. Genetic distances are shown for Patients 6–11. Each pre-
lamivudine sequence was plotted according to its value in two dimensions: 
the average distance to all other pre-treatment variants (x axis) and the 
average distance to all other post-treatment variants (y axis). 
6 7 8 Spacer
9 10 11
tp
rt
rh
preS1
preS2
HBsAg
X
HBcAg
rt180
rt204
TS
Figure 5 | BNs of intra-host HBV variants from Patients 6–11. Tp, spacer, rt and rh—terminal protein, spacer, RT and RnAse H domains of the HBV 
P protein; s1, s2 and hepatitis B surface antigen (HBsAg)—pres1, pres2 and s domains of the HBV s protein; X, the X protein; hepatitis B core antigen 
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constructed using only the pre-treatment subpopulations, which were 
genetically close to the resistant HBV variants.
In each patient, 45–100% of all polymorphic amino-acid sites 
were organized in a single network. In Patients 6 and 7, whose drug-
resistant HBV variants mainly evolved from the major pre-treatment 
subpopulations, only 66 (58%) and 28 (45%) sites, respectively, were 
involved in BN. In Patients 8, 9, 10 and 11, whose drug-resistant 
HBV variants evolved from minority subpopulations, the number of 
sites in BN varied from 66 to 202 (76–100% of all polymorphic sites). 
HBV BN from Patients 6, 7, 8, 10 and 11 included rt204 and rt180, 
indicating that the state of these lamivudine-resistance sites depends 
on other sites in the HBV genome. The lamivudine-resistance sites 
were  found  to  be  significantly  interrelated  to  each  other  and  to   
several sites from the HBV C, S, X and P proteins (P < 0.0001; Fig. 5).
Discussion
HBV resistance to lamivudine is considered to be primarily associ-
ated with point mutations, such as rtM204I/V and rtA181V/T (ref. 3).   
The data presented in this study indicate that, although essential, the 
mere presence of rtM204V/I is not sufficient for the development of 
the HBV lamivudine-resistance. For example, single HBV variants 
that carried the rtM204I substitution before therapy in Patients 6 
and 9 were unsuccessful in establishing detectable intra-host HBV 
populations after treatment. For Patient 6, the lamivudine-resistant 
HBV population originated mainly from the pre-treatment major-
ity variant. In Patient 9, the pre-treatment rtM204I-carrying variant 
belonged to genotype G but only recombinant A/G variants became 
established after treatment.
The  calculated  high  rate  of  mutations  ranging  from  10 − 4  to 
10 − 5 mutations per site per year11,12 coupled with the estimated 
daily production of HBV in excess of 1011–1013 virions13,14 theo-
retically can result in daily generation of all single substitutions at 
each site of the HBV genome5 or even all possible double substitu-
tions14. Thus, the lamivudine-resistance substitutions may readily 
emerge during the course of HBV infection and be present in the 
intra-host HBV population in patients who have not been exposed 
to treatment. Indeed, these substitutions were recently detected by 
ultra-deep sequencing of HBV variants from treatment-naïve and 
lamivudine-treated patients15. The observations of two large HBV 
subpopulations (both developing lamivudine resistance) in Patient 
1, the lamivudine-resistant minority subpopulations in Patients 5, 
6 and 11 and more than one type of lamivudine-resistance muta-
tions in Patients 2, 3 and 10 strongly support this supposition of fre-
quent presentation of lamivudine-resistance substitutions. In each 
case, the lamivudine-resistance substitutions have been independ-
ently acquired by more than one HBV variant, indicating recurrent, 
convergent evolution toward lamivudine resistance in patients who 
developed breakthrough infection.
The observed homoplasy and convergence rooted in the high 
rate of mutations are not compatible with the commonly assumed 
origination of the intra-host drug-resistant viral populations from 
a single viral clone. The development of lamivudine resistance in 
the patients studied here cannot be explained by the random pres-
entation of point mutations. The emergence of these mutations is 
not a limiting factor in the development of drug resistance. Rather, 
our data indicate that the genetic structure of the HBV genome is 
critical in selecting variants capable of taking advantage of these 
mutations under the selection pressure of antiviral therapy. The dif-
ferential capacity of the intra-host HBV subpopulations to lamivu-
dine resistance observed in Patients 8, 9, 10 and 11 suggests that the 
fitness effects of lamivudine-resistance mutations varied depending 
on the genetic composition of the viral genome. This supposition 
is  strongly  supported  by  analysis  of  BNs  connecting  polymor-
phic amino-acid sites from HBV proteins in Patients 6–8, 10 and 
11. These networks showed that the states of rt204 and rt180 are 
strongly associated with the states of many other sites from all HBV   
proteins,  thereby  highlighting  the  role  of  epistatic  connectivity   
and coevolution among sites across the entire HBV genome in the 
development of drug resistance6.
Finally, findings from this study suggest that differential pre-
disposition to drug-resistance for HBV variants is a more realistic 
framework for understanding disparity in the development of drug 
resistance among patients than the fortuitous emergence of resist-
ance mutations. This predisposition can be assessed and used to 
predict response to treatment. As predisposition to resistance is 
defined by the entire genome rather than by a single independent 
mutation, it cannot revert upon cessation of treatment. Lamivudine 
is widely used in treating patients with HBV mono-infection par-
ticularly in resource-limited countries and is an important compo-
nent of anti-retroviral therapy for patients co-infected with HBV 
and human immunodeficiency virus. Thus, the widespread use of 
lamivudine favors selection of HBV variants with genetic composi-
tion that is predisposed to resistance to this drug, potentially lead-
ing to a genetic shift in the HBV population toward the increased 
resistance. Although lamivudine is no longer a first-line drug in 
developed countries, the concept as proposed here should be appli-
cable to other antiviral drugs. Furthermore, HBV variants resistant 
to lamivudine are also resistant to telbivudine and less susceptible 
to entecavir16,17, indicating that selection for lamivudine resistance 
may result in increased likelihood of cross-resistance to other drugs. 
Therefore, our findings may have implications for improving the 
efficacy of antiviral therapy against HBV infection.
Methods
HBV whole-genome quasispecies analysis. Full-length HBV genome was 
amplified by two rounds of PCR11. Briefly, the first round of PCR was conducted 
using the primer combination of HBV1823FLong and HBV1801RLong (Table 2). 
The thermal profile for the first-round amplification was as follows: 94 °C for 3 min 
(hold), ten cycles of 94 °C for 20 s, 55–45 °C for 30 s with step-down of 1 °C per 
cycle and 68 °C for 4 min; 35 cycles of 94 °C for 20 s, 45 °C for 30 s, 68 °C for 4 min 
with increasing elongation time for 10 s per cycle to 7 min 20 s and the final elonga-
tion at 68 °C for 10 min. The first-round PCR was performed on the GeneAmp 
PCR system 9,700 (Applied Biosystems, Foster City, CA, USA) using the Expand 
High-Fidelity PCR test kit. The second-round PCR was conducted using six sets of 
primers (set 1: HBV1847FS and HBV2394RS, set 2: HBV2298FS and HBV2933RS, 
set 3: HBV2821FS and HBV0272RS, set 4: HBV0179FS and HBV0704RS, set 5: 
HBV0599FS and HBV1286RS and set 6: HBV1175FS and HBV1788RS) for ampli-
fication of six overlapping fragments (Table 2) under the following cycling condi-
tions: 95 °C for 10 min (hold), 40 cycles of 95 °C for 10 s, 45 °C for 10 s and 72 °C for 
32 s. The nested amplification was performed by using the Mx3005P SYBR Green 
Real-Time PCR System (Stratagene, La Jolla, CA, USA). The derivative melting 
curves were obtained using the instrument data analysis software.
End-point limiting-dilution-PCR was performed using serially diluted DNA18. 
Dilution, at which 20–30% of PCR repeats were found positive, was considered as 
the endpoint. Nested PCR of the 441-bp fragment of the S gene (primer set 4) was 
used to establish this condition. All six sets of PCR fragments were amplified using 
the same end-point dilution. Clone selection, serial dilution and reagent dispensing 
were performed using the Biomek 3,000 robotic station (Beckman-Coulter, Brea, 
CA, USA). Approximately 30–40 whole-genome clones were amplified from each 
sample. The number of clones varied depending on viral titre of samples.
Genetic analysis. Multiple sequences alignment was performed using pro-
grammes in Accelrys GCG, Version 11.0. (Genetic Computer Group, Accelrys 
Inc., San Diego, CA, USA). The extent of HBV genetic diversity for each patient 
was measured as the average Sn over all genomic positions. Sn of each position 
was measured as S =  − Σ(pi ln pi), where pi is the frequency of each nucleotide. 
The normalized entropy Sn = S/ln N was calculated to take into consideration the 
total number of sequences (N) obtained in each patient. To test whether the HBV 
genetic diversity was significantly changed between the pre- and post-treatment  
in each patient, we performed a paired samples t-test for all HBV genomic 
positions. AMOVA was used to identify positions with significant changes of 
nucleotide frequency between HBV variants found before and after lamivudine 
treatment. Estimates of φst were used to analyse the genetic structure of HBV 
population by taking into consideration differences in frequency and composition 
of sequence variants. AMOVA was calculated using the program ARLEQUIN19; 
significance levels of the genetic variance components were estimated using a 
permutation test (n = 10,000).
Phylogenetic analysis. The program ModelTest20 was used to establish the best 
model of nucleotide substitution for the HBV data. The GTR model was chosen to ARTICLE     
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create maximum likelihood trees21 using the program HyPHY22. The initial tree 
was created using the neighbour-joining approach23, a search in the tree space was 
performed using nearest neighbor interchange of branches on the tree until no 
further likelihood score improvements could be made.
Maximum likelihood distance matrix. The program HyPHY22 was used to create 
a maximum likelihood distance matrix21 among HBV sequences. This distance 
matrix was used to create a scatterplot, where each pre-lamivudine sequence was 
plotted according to its value in two dimensions: the average distance to all other 
pre- or post-treatment sequences.
Bayesian network. Relationships among HBV protein sites from pre- and post-
treatment populations were examined using probabilistic graphical models in the 
form of BNs24. For each patient, the aligned sequences were associated with the 
sampling time; namely, pre- or post-treatment. States of polymorphic sites and 
sequence sampling time-point constituted the entire set of viral features. Sequence 
deletions in HBV variants were also encoded as a feature and represented as a node 
in BN. Learning of the BN structure was based on the Greedy Thick Thinning 
method25, where the structure was constrained so that any given node in BN  
could have no greater than three parents. Estimation of the conditional  
probabilities was performed using the K2 priors of each feature26.
In addition, relationship analysis of the HBV BN was performed to infer 
significance/strength of relationships between the features. The strength of the 
probabilistic relations between variables that it represents in the global probability 
law was measured by computing the Kullback–Leibler (KL) divergence27 between 
the joint probability distribution of a relation with and without the arc. This is a 
measure of dependence between variables. The P-values represent the independ-
ence probabilities of the G-KL–test computed on the BN for each relationship, 
where G-KL is the independence G test of KL divergence of the relationship in 
the network. This analysis was done using the BayesiaLab (v4.6) software package 
(Bayesia SAS, Laval, France).
Nucleotide sequence accession numbers. The whole-genome sequences  
produced in this study have been deposited in the National Center for  
Biotechnology Information GenBank database under accession numbers 
JQ707299–JQ707774.
Ethics statement. Serum specimens of all patients were acquired with  
written informed consent, and the study involving human participants was  
approved by the Institutional Review Board of Centers for Disease Control  
and Prevention. 
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Table 2 | PCR primers.
Primer name Primer sequence
HBV1798FLong* 5′-CTGCGCACCAGCACCATGCAACTTTTTC-3′
HBV1801RLong 5′-CAGACCAATTTATGCCTACAGCCTCCTA-3′
HBV1847Fs 5′-CGATTTAGGTGACACTATAGAAGAGAGG 
CTTGTTCATGTCCCACTGTTCAA-3′
HBV2394Rs 5′-CAGTAATACGACTCACTATAGGGAGAAG 
GCTGGCGAGGGAGTTCTT-3′
HBV2298Fs 5′-CGATTTAGGTGACACTATAGAAGAGAGG 
CTGACCACCAAATGCCCCTAT-3′
HBV2933Rs 5′-CAGTAATACGACTCACTATAGGGAGAAG 
GCTTCGGGAAAGAATCCCAGAGGAT-3′
HBV2821Fs 5′-CGATTTAGGTGACACTATAGAAGAGAGG 
CTGGTCACCATATTCTTGGGAAC-3′
HBV0272Rs 5′-CAGTAATACGACTCACTATAGGGAGAAG 
GCTTGAGAGAAGTCCACCACGAGT-3′
HBV0179Fs 5′-CGATTTAGGTGACACTATAGAAGAGAGG 
CTCTAGGACCCCTGCTCGTGTT-3′
HBV0704Rs 5′-CAGTAATACGACTCACTATAGGGAGAAG 
GCTCGAACCACTGAACAAATGGCACT-3′
HBV0599Fs 5′-CGATTTAGGTGACACTATAGAAGAGAGG 
CTGTATTCCCATCCCATCATCCTG-3′
HBV1286Rs 5′-CAGTAATACGACTCACTATAGGGAGAAG 
GCTGCTAGGAGTTCCGCAGTATGG-3′
HBV1175Fs 5′-CGATTTAGGTGACACTATAGAAGAGAGG 
CTGCCAAGTGTTTGCTGA-3′
HBV1788Rs 5′-CAGTAATACGACTCACTATAGGGAGAAG 
GCTGCCTACAGCCTCCTA-3′
sP6† 5′-CGATTTAGGTGACACTATAGAAGAGAGG 
CT-3′
T7† 5′-CAGTAATACGACTCACTATAGGGAGAAG 
GCT-3′
*numbers within the primer ID represent the sequence location within the HBV genome.
†sP6 and T7 are tag sequences attached at the 5′ end of all PCR primers used in this study. 
specific sP6 and T7 primers were used to sequence PCR fragments.ARTICLE
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